000			02039 a2200529 4500
005			20250513184759.0
264		0	_c19990916
008			199909s 0 0 eng d
022			_a0305-7453
024	7		_a10.1093/jac/43.5.741 _2doi
040			_aNLM _beng _cNLM
100	1		_aSchröder, C P
245	0	0	_aPrevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. _h[electronic resource]
260			_bThe Journal of antimicrobial chemotherapy _cMay 1999
300			_a741-3 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial
650	0	4	_aAdult
650	0	4	_aAmphotericin B _xeconomics
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aCiprofloxacin _xeconomics
650	0	4	_aCosts and Cost Analysis
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEpirubicin _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aFever _xcomplications
650	0	4	_aFluorouracil _xadministration & dosage
650	0	4	_aGranulocyte Colony-Stimulating Factor _xeconomics
650	0	4	_aHumans
650	0	4	_aLength of Stay _xeconomics
650	0	4	_aLeukopenia _xchemically induced
650	0	4	_aMethotrexate _xadministration & dosage
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Metastasis
650	0	4	_aNetherlands
650	0	4	_aProspective Studies
650	0	4	_aRecombinant Proteins _xeconomics
700	1		_ade Vries, E G
700	1		_aMulder, N H
700	1		_aWillemse, P H
700	1		_aSleijfer, D T
700	1		_aHospers, G A
700	1		_avan der Graaf, W T
773	0		_tThe Journal of antimicrobial chemotherapy _gvol. 43 _gno. 5 _gp. 741-3
856	4	0	_uhttps://doi.org/10.1093/jac/43.5.741 _zAvailable from publisher's website
999			_c10341258 _d10341258